Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Arcus Biosciences, Inc. (NYSE: RCUS).

Full DD Report for RCUS

You must become a subscriber to view this report.


Recent News from (NYSE: RCUS)

Key events next week - healthcare
Noteworthy events during the week of November 4 - 10 for healthcare investors. More news on: Dare Bioscience, Inc., EyePoint Pharmaceuticals, Inc., Aduro Biotech, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: November, 02 2018 10:12
Arcus Biosciences Announces Participation at Three Investor Conferences in November
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that members of the management team will participate at the following upcoming investor conferences: Credit Suisse 27th Annual Healthca...
Source: Business Wire
Date: November, 01 2018 16:05
Arcus Biosciences Appoints Kristen M. Hege, M.D., to its Board of Directors
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced the appointment of Kristen M. Hege, M.D., to its Board of Directors. Dr. Hege brings more than 20 years of oncology clinical leadership exper...
Source: Business Wire
Date: October, 22 2018 08:30
Arcus Biosciences: 5 Reasons Why It's A Good Idea After All.
The probability of success from Phase 1 to approval in pharmaceutical research is 10% in general and only 5% for oncology research in particular. So, is it a good idea to invest in an early-stage biopharmaceutical company focusing on cancer like Arcus Biosciences ( RCUS )? We believe the ans...
Source: SeekingAlpha
Date: October, 09 2018 10:52
Arcus Biosciences to Present Final Results from the Phase 1 Study of AB928 in Healthy Volunteers at ESMO 2018 Congress
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that it will present final results from the Phase 1 study of AB928, its dual adenosine receptor antagonist, in healthy volunteers during a po...
Source: Business Wire
Date: October, 08 2018 18:40
Arcus Biosciences Announces Nine Abstracts Accepted for Presentation at the SITC 2018 Annual Meeting
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that nine abstracts have been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, which i...
Source: Business Wire
Date: October, 02 2018 16:30
Stocks To Watch: Apple Event, Chinese Auto IPO To Headline
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. All eyes in the tech sector will be on Apple's (AAPL) special event scheduled for S...
Source: SeekingAlpha
Date: September, 08 2018 07:29
Compugen, 'From Code To Cure': Becoming A Clinical-Stage Company
With a market cap of only $225 million (including $43 million in cash as of June 30th), Compugen Ltd. ( CGEN ) has the potential to deliver outsized returns for shareholders over the next 12 to 24 months. Since publishing my initial article on Compugen on SA on February 20, 2018, Compugen ...
Source: SeekingAlpha
Date: September, 05 2018 10:11
Daily Insider Ratings Round Up 8/29/18
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Source: SeekingAlpha
Date: August, 31 2018 15:30
Daily Insider Ratings Round Up 8/24/18
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signif...
Source: SeekingAlpha
Date: August, 28 2018 13:32

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-1413.2314.1914.480313.23152,053

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1033,20034,35196.6493Short
2018-12-071,3001,33597.3783Short
2018-12-062,4482,81087.1174Short
2018-12-045,7037,85372.6219Short
2018-12-037732,33533.1049Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RCUS.


About Arcus Biosciences, Inc. (NYSE: RCUS)

Logo for Arcus Biosciences, Inc. (NYSE: RCUS)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NYSE: RCUS)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: August, 06 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: August, 06 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: July, 12 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: June, 12 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 09 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 09 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: March, 23 2018
      Prospectus filed under Rule 424(b)(4)
      Filing Type: 424B4Filing Source: edgar
      Filing Date: March, 16 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 16 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: March, 15 2018

       

       


      Daily Technical Chart for (NYSE: RCUS)

      Daily Technical Chart for (NYSE: RCUS)


      Stay tuned for daily updates and more on (NYSE: RCUS)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NYSE: RCUS)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RCUS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of RCUS and does not buy, sell, or trade any shares of RCUS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/